The effect of caffeine on cerebral metabolism during alpha-chloralose anesthesia differs from isoflurane anesthesia in the rat brain.
Anesthesia
/ methods
Anesthetics
/ pharmacology
Animals
Brain
/ diagnostic imaging
Caffeine
/ pharmacology
Central Nervous System Stimulants
/ pharmacology
Chloralose
/ pharmacology
Dose-Response Relationship, Drug
Isoflurane
/ pharmacology
Male
Positron-Emission Tomography
/ methods
Rats
Rats, Sprague-Dawley
18F-FDG
Anesthesia
Caffeine
Cerebral metabolism
Concentration
PET
Journal
Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
09
05
2018
accepted:
19
12
2018
pubmed:
4
1
2019
medline:
29
10
2019
entrez:
4
1
2019
Statut:
ppublish
Résumé
Caffeine is a widely studied psychostimulant, even though its exact effect on brain activity remains to be elucidated. Positron emission tomography (PET) allows studying mechanisms underlying cerebral metabolic responses to caffeine in caffeine-naïve rats. Rodent studies are typically performed under anesthesia. However, the anesthesia may affect neurotransmitter systems targeted by tested drugs. The scope of the present study was to address the impairing or enhancing effect of two common anesthetics, alpha-chloralose and isoflurane, on the kinetics of caffeine. The first group of rats (n = 15) were anesthetized under 1.5% isoflurane anesthesia. The second group of rats (n = 15) were anesthetized under alpha-chloralose (80 mg/kg). These rats received an intravenous injection of saline (n = 5) or of 2.5 mg/kg (n = 5) or 40 mg/kg (n = 5) caffeine for both groups. With 2.5 mg/kg or 40 mg/kg caffeine, whole-brain cerebral metabolism was significantly reduced by 17.2% and 17% (both P < 0.01), respectively, under alpha-chloralose anesthesia. However, the lower dose of caffeine (2.5 mg/kg) had a limited effect on brain metabolism, whereas its higher dose (40 mg/kg) produced enhancements in brain metabolism in the striatum, hippocampus, and thalamus (all P < 0.05) under isoflurane anesthesia. These findings demonstrate significant differences in brain responses to caffeine on the basic of the anesthesia regimen used, which highlights the importance of attention to the anesthetic used when interpreting findings from animal pharmacological studies because of possible interactions between the anesthetic and the drug under study.
Identifiants
pubmed: 30604185
doi: 10.1007/s00213-018-5157-4
pii: 10.1007/s00213-018-5157-4
doi:
Substances chimiques
Anesthetics
0
Central Nervous System Stimulants
0
Chloralose
238BZ29MUE
Caffeine
3G6A5W338E
Isoflurane
CYS9AKD70P
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1749-1757Subventions
Organisme : Ministry of Science and Technology, Taiwan
ID : MOST 105-2314-B-039-044-MY2
Références
Pharmacol Rev. 1999 Mar;51(1):83-133
pubmed: 10049999
Cell Mol Neurobiol. 1999 Dec;19(6):719-32
pubmed: 10456233
Anesthesiology. 1999 Dec;91(6):1788-97
pubmed: 10598623
Brain Res. 2000 Mar 6;858(1):71-7
pubmed: 10700599
Annu Rev Neurosci. 2001;24:31-55
pubmed: 11283304
Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7593-8
pubmed: 11390971
Magn Reson Med. 2001 Jul;46(1):202-6
pubmed: 11443729
Neuropsychopharmacology. 2001 Dec;25(6):925-35
pubmed: 11750185
Neuropsychopharmacology. 2002 Aug;27(2):182-93
pubmed: 12093592
J Neurosci. 2002 Aug 1;22(15):6321-4
pubmed: 12151508
Food Chem Toxicol. 2002 Sep;40(9):1257-61
pubmed: 12204389
Neuroimage. 2002 Oct;17(2):751-7
pubmed: 12377150
Vet Anaesth Analg. 2003 Jan;30(1):15-23
pubmed: 14498913
Ann Nucl Med. 2003 Sep;17(6):511-5
pubmed: 14575390
Eur J Anaesthesiol. 2003 Oct;20(10):800-8
pubmed: 14580049
J Vet Pharmacol Ther. 2003 Oct;26(5):369-76
pubmed: 14633190
Synapse. 2005 Feb;55(2):133-6
pubmed: 15543628
Acta Anaesthesiol Scand. 1992 May;36(4):318-22
pubmed: 1595336
Cereb Cortex. 2007 Apr;17(4):942-50
pubmed: 16731882
Curr Opin Anaesthesiol. 2007 Aug;20(4):300-6
pubmed: 17620835
Neuron. 2007 Dec 6;56(5):771-83
pubmed: 18054855
Nature. 2008 Jun 12;453(7197):869-78
pubmed: 18548064
Neuroscience. 2008 Sep 9;155(4):1221-6
pubmed: 18675887
Neuropsychopharmacology. 2009 Mar;34(4):972-86
pubmed: 18800071
J Neurosci. 2009 Mar 11;29(10):3036-44
pubmed: 19279240
Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1582-7
pubmed: 20080687
J Alzheimers Dis. 2010;20 Suppl 1:S35-49
pubmed: 20182056
Magn Reson Imaging. 2010 Sep;28(7):995-1003
pubmed: 20456892
J Cereb Blood Flow Metab. 2011 Jun;31(6):1432-42
pubmed: 21266982
Neuroimage. 2011 Aug 1;57(3):809-16
pubmed: 21586328
Neuroimage. 2011 Sep 1;58(1):75-81
pubmed: 21708273
J Cereb Blood Flow Metab. 2013 Jun;33(6):963-8
pubmed: 23486295
J Neurophysiol. 2014 Mar;111(6):1331-40
pubmed: 24375022
Magn Reson Imaging. 2014 May;32(4):366-71
pubmed: 24512799
Mol Pharm. 2014 Nov 3;11(11):3904-14
pubmed: 25153169
Neuroimage. 2015 Apr 15;110:39-47
pubmed: 25644657
Eur Neuropsychopharmacol. 2016 Mar;26(3):518-31
pubmed: 26796682
PLoS One. 2016 May 05;11(5):e0154936
pubmed: 27148970
Neuroimage. 2017 Jul 15;155:331-343
pubmed: 28323164
Front Psychiatry. 2017 Nov 01;8:218
pubmed: 29163237
Neuroimage. 2018 May 15;172:9-20
pubmed: 29414498
J Nucl Med. 1985 Jan;26(1):72-6
pubmed: 3965655
Eur J Pharmacol. 1971 Nov-Dec;16(3):322-5
pubmed: 5132559
Eur J Pharmacol. 1970 Apr;10(1):64-71
pubmed: 5458986
Eur J Pharmacol. 1984 May 18;101(1-2):91-100
pubmed: 6086367
Am J Physiol. 1993 Apr;264(4 Pt 2):H1223-8
pubmed: 8476099
Naunyn Schmiedebergs Arch Pharmacol. 1993 Apr;347(4):407-14
pubmed: 8510768
J Pharmacol Exp Ther. 1998 May;285(2):680-6
pubmed: 9580613
Eur J Neurosci. 1998 Nov;10(11):3379-86
pubmed: 9824451
Am J Psychiatry. 1999 Feb;156(2):229-37
pubmed: 9989559